ALT "Astellas and Bayer actually have kind of blazed the trail for us here, and what we're looking for is a statistically significant and clinically meaningful reduction in the frequency and severity of hot flashes at the four-week endpoint. Specifically in terms of the frequency, what we'd be looking for is a reduction of at least 2 moderate to severe hot flashes per day, and that would be on the order of what the clinical efficacy has been of the approved small molecules. And that is off of a baseline where we've been screening really moderate to severe hot flashes with, you know, let's say, similar to Veozah and Lynkuet, of about 50 hot flashes a week. So, on the order of 7 or 8 per day? And so it would be a reduction of about that 20% of those hot flashes, or 2 per day, would be equivalent efficacy of the small molecules..." — AbCellera CFO Andrew Booth at Jefferies Global Healthcare Conference 2026 | June 4, 2026 $ABCL
ALT AbCellera CFO Andrew Booth speaking at Jefferies Global Healthcare Conference 2026 on June 4, 2026 $ABCL
ALT Stanley Druckenmiller's Duquesne Family Office purchased 206,000 shares of Twist worth about $9.7 million in Q1 2026 $TWST
ALT U.S. Department of Energy | Genesis Mission National Science and Technology Challenges Scaling the Biotechnology Revolution Al Solution: Al will integrate and interpret genomics, multi-omics, imaging, dynamics, and phenomics data into embedded models to establish genotype-phenotype relationships, identify causal control points, and guide autonomous experimentation. This will advance Al's ability to reason about long causal chains under uncertainty, integrate across multiple scales, and learn from sparse, noisy data. Tools like digital twins could be used to derisk process development, optimization, integration, and scale-up, thereby speeding up industrial production of biofuels, biochemicals, and bioproducts by orders of magnitude.
ALT U.S. Department of Energy | Genesis Mission National Science and Technology Challenges Achieving AI-Driven Autonomous Laboratories Al Solution: Artificial intelligence will be integrated directly into the experimental workflow and data analysis, combining robotics, edge AI, real-time analysis and intelligent feedback, hypothesis generation, and data curation/sharing.
ALT The mission explicitly mandates the exploration of international scientific collaboration opportunities under section 5(d). The operational framework identifies Canada as an explicit target country under the "Trusted Ally Research Consortia" model. According to the text, participation for Canadian entities is enabled through: Pre-Competitive Science: Collaborative research frameworks focusing on foundational science where the U.S. maintains a structural advantage. Data-Sharing Agreements: Standardized data-sharing and model-use templates for unclassified research. Consortium-Based Joint Initiatives: Participating as an international partner aligned with university-led or multi-organizational research networks.
ALT "DNA synthesis vulnerabilities: Companies such as Twist Bioscience screen every order to prevent misuse, serving as a frontline defense where digital code becomes physical biology. But screening remains voluntary and inconsistent. Despite bipartisan and industry support, no enforceable federal standards exist. Some companies use rigorous protocols, others rely on partial measures, and some do not screen at all. This uneven adoption leaves openings for misuse of genetic material and creates biosecurity vulnerabilities." $TWST
ALT "There are some other elements that we negotiated with the FDA that are likely to facilitate things. And, you know, potentially facilitate things. Um, and expedite, the process a little bit. We have not publicly disclosed that just yet because of, you know, just for competitive reasons." AtaiBeckley CEO Srinivas Rao at Jefferies answering a question about the timeline for BPL-003 $ATAI
ALT As previously announced, AtaiBeckley (the “Company”) will participate in multiple upcoming investor conferences in June 2026, as set forth below. Management will discuss program updates, including the initiation of the BPL-003 Phase 3 pivotal ReConnection program, and other matters. Source: 06-03-2026 8K
ALT "In terms of where things currently stand with BPL-003, we actually just initiated our phase 3 program as of today. Or at least we announced that as of today." — Srinivas Rao, CEO of AtaiBeckley at Jefferies 2026